BioMarin Wins Approval for First Dwarfism Medicine in Europe

BioMarin Pharmaceutical Inc.’s drug for the most common form of dwarfism won approval in Europe, the first targeted therapy to be sold for children with the condition.

The European Commission authorized the once-daily injection, called Voxzogo, for use in children from the age of 2 until growth plates -- areas of cartilage at the ends of long bones -- close at the end of puberty, which is when people reach their final height. The achondroplasia drug is the first of its kind approved in Europe. The U.S. Food and Drug Administration is expected to finish its own review by ...